Protara Therapeutics
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 27
- Market Cap
- $42.4M
- Website
- http://www.protaratx.com
- Introduction
Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer
- Conditions
- Non-muscle Invasive Bladder Cancer
- Interventions
- Biological: TARA-002
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Protara Therapeutics
- Target Recruit Count
- 127
- Registration Number
- NCT05951179
- Locations
- ๐บ๐ธ
Urology Associates of Denver, Lone Tree, Colorado, United States
๐บ๐ธSouthern Urology, Lafayette, Louisiana, United States
๐บ๐ธConrad Person Clinic, Memphis, Tennessee, United States
Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age
- Conditions
- Lymphatic Malformation
- Interventions
- Biological: TARA-002
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Protara Therapeutics
- Target Recruit Count
- 38
- Registration Number
- NCT05871970
- Locations
- ๐บ๐ธ
Oregon Health & Science University, Portland, Oregon, United States
๐บ๐ธChildren's Hospital of Alabama, Birmingham, Alabama, United States
๐บ๐ธArkansas Children's Hospital/UAMS, Little Rock, Arkansas, United States
Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)
- Conditions
- Non-muscle Invasive Bladder Cancer
- Interventions
- Biological: TARA-002
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Protara Therapeutics
- Target Recruit Count
- 10
- Registration Number
- NCT05085990
- Locations
- ๐บ๐ธ
Chesapeake Urology Research Associates, Baltimore, Maryland, United States
๐บ๐ธUrology Associates PC, Nashville, Tennessee, United States
๐บ๐ธCarolina Urologic Research Center, Myrtle Beach, South Carolina, United States
Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)
- Conditions
- Non-muscle Invasive Bladder Cancer
- Interventions
- Biological: TARA-002
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Protara Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT05085977
- Locations
- ๐บ๐ธ
New Jersey Urology, Mount Laurel, New Jersey, United States
๐บ๐ธCarolina Urologic Research Center, Myrtle Beach, South Carolina, United States
๐ฒ๐ฉPMSI Republican Clinical Hospital "T. Mosneaga," ARENSIA Exploratory Medicine Phase I Unit, Chisinau, Moldova, Republic of
Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition
- Conditions
- Intestinal Failure-associated Liver Disease
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Protara Therapeutics
- Target Recruit Count
- 80
- Registration Number
- NCT05011370
- Locations
- ๐บ๐ธ
IHS Health, Kissimmee, Florida, United States
๐บ๐ธThe University of Chicago, Chicago, Illinois, United States
๐บ๐ธVirginia Commonwealth University, Richmond, Virginia, United States